PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
M He, C Cao, Z Ni, Y Liu, P Song, S Hao, Y He… - … and Targeted Therapy, 2022 - nature.com
Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
H Lu, Q Zhou, J He, Z Jiang, C Peng, R Tong… - Signal transduction and …, 2020 - nature.com
Protein–protein interactions (PPIs) have pivotal roles in life processes. The studies showed
that aberrant PPIs are associated with various diseases, including cancer, infectious …
that aberrant PPIs are associated with various diseases, including cancer, infectious …
RAS-targeted therapies: is the undruggable drugged?
AR Moore, SC Rosenberg, F McCormick… - Nature reviews Drug …, 2020 - nature.com
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …
structures or functions that are difficult to interfere with using conventional drug design …
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
L Buscail, B Bournet, P Cordelier - Nature reviews Gastroenterology & …, 2020 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …
cause of death within the next 10 years. The prognosis for this disease is poor despite …
RAS proteins and their regulators in human disease
DK Simanshu, DV Nissley, F McCormick - Cell, 2017 - cell.com
RAS proteins are binary switches, cycling between ON and OFF states during signal
transduction. These switches are normally tightly controlled, but in RAS-related diseases …
transduction. These switches are normally tightly controlled, but in RAS-related diseases …
[HTML][HTML] Targeting the untargetable KRAS in cancer therapy
P Liu, Y Wang, X Li - Acta Pharmaceutica Sinica B, 2019 - Elsevier
RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …
NBD-based synthetic probes for sensing small molecules and proteins: design, sensing mechanisms and biological applications
Compounds with a nitrobenzoxadiazole (NBD) skeleton exhibit prominent useful properties
including environmental sensitivity, high reactivity toward amines and biothiols (including …
including environmental sensitivity, high reactivity toward amines and biothiols (including …
Protein lipidation: occurrence, mechanisms, biological functions, and enabling technologies
Protein lipidation, including cysteine prenylation, N-terminal glycine myristoylation, cysteine
palmitoylation, and serine and lysine fatty acylation, occurs in many proteins in eukaryotic …
palmitoylation, and serine and lysine fatty acylation, occurs in many proteins in eukaryotic …